Phase II trial of 4'-deoxydoxorubicin (DxDx) in non-small cell lung cancer: a Cancer and Leukemia Group B Trial.

Abstract

Eighty-seven patients with histologically or cytologically proven non-small-cell carcinoma of the lung were treated with 4'-deoxydoxorubicin (DxDx) 30 mg/m2 every 3 weeks. Three responses (4%), all partial, were observed. All responses occurred in patients with large-cell anaplastic lung cancer and none in squamous or adenocarcinoma histologies (P less than 0.01). The durations of partial response for these three responders were 70, 198+ and 209+ days. The side effects noted were predominantly neutropenia, anemia, and weight loss. In three patients, declines in cardiac ejection fraction of 7%, 12%, and 23% occurred after cumulative drug doses of 150 mg/m2, 150 mg/m2, and 233 mg/m2, respectively. 4'-Deoxydoxorubicin had little activity in non-small-cell lung cancer at the dose used in this study.

• Authors: Q S Ringenberg, M C Perry, K J Propert, C Modeas, V Hirsh, R B Weiss, F Richards 2nd, S Graziano, M Green
• Journal: Medical and pediatric oncology (Med Pediatr Oncol) Vol. 16 Issue 1 Pg. 27-9 ( 1988) ISSN: 0098-1532 [Print] United States
• PMID: 2828901 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Doxorubicin
• esorubicin

Topics

• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Doxorubicin (analogs & derivatives, therapeutic use)
• Drug Evaluation
• Humans
• Lung Neoplasms (drug therapy)